Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L

Slides:

Advertisements

Similar presentations

Objective assessment of gastroesophageal reflux after short esophagomyotomy for achalasia with the use of manometry and pH monitoring John M. Streitz,

Advertisements

Robert C. Gorman, MDa(by invitation), Nicholas P

Peter E. Ballmer, MDa, Walter H

Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model Paul M. Petre, MDa, Frank A. Baciewicz, MDb, Stefan.

Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts Sidney Chocron, MDa, Kifah Alwan, MDa, Gerard Toubin, MDb,

Changes in cysteinyl leukotrienes during and after cardiac surgery with cardiopulmonary bypass in patients with and without chronic obstructive pulmonary.

Reopro removal during cardiopulmonary bypass using a hemoconcentrator

Jacek M. Karski, MDa, Sally J

Peter E. Ballmer, MDa, Walter H

The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations Dennis Bigler, MDa, Torsten Jonsson, MDa, Johnny Olsen,

Esmolol and percutaneous cardiopulmonary bypass enhance myocardial salvage during ischemia in a dog model Glenn W. Laub, MD, S. Muralidharan, MD, Jerome.

Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? Song Wan, MD, PhDa, Jean-Louis LeClerc, MDb, Chi-Hoang Huynh,

Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model Paul M. Petre, MDa, Frank A. Baciewicz, MDb, Stefan.

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

The effects of normothermic and hypothermic cardiopulmonary bypass on defibrillation energy requirements and transmyocardial impedance David Martin,

M. Griese, MD, C. Wilnhammer, MD, S. Jansen *, C. Rinker, MD

Oz M. Shapira, MDa, Aiming Xu, PhDb, Joseph A. Vita, MDb, Gabriel S

The effects of carmeda bioactive surface on human blood components during simulated extracorporeal circulation Robert L. Korn, MD, PhD, Carol A. Fisher,

Steven R. Gundry, MD, Matthew A. Romano, MD, O

Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting Harold L. Lazar, MDa, George Philippides, MDb, Carmel.

Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: One size doesn't fit all David Faraoni, MD,

The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function: A clinical study Tomislav Mihaljevic, MDa, Martin.

Harold L. Lazar, MD The Journal of Thoracic and Cardiovascular Surgery

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery John L Francis, PhD, George J Palmer, MD, Rebecca Moroose,

The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass Elijah W. Muriithi,

Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass Alvise Bernabei,

Effects of cryopreservation on contractile properties of porcine isolated aortic valve leaflets and aortic wall Claes Wassenaar, MD, PhDa, Willem A.

Changes in cysteinyl leukotrienes during and after cardiac surgery with cardiopulmonary bypass in patients with and without chronic obstructive pulmonary.

Biocompatibility of heparin-coated extracorporeal bypass circuits: A randomized, masked clinical trial Derek D. Muehrcke, MDa, Patrick M. McCarthy, MDa,

Oxygen consumption after cardiopulmonary bypass surgery in children: Determinants and implications Jia Li, MDa, Ingram Schulze-Neick, MDa, Christopher.

Richard J. Novick, MDa, Ruud A. W

Editorial: The core of leadership

Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated.

Effects of selectin–sialyl Lewisx blockade on mesenteric microvascular permeability associated with cardiopulmonary bypass Charles S. Cox, MD, Steven.

Support Your Specialty

Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass

Cerebral hyperthermia during cardiopulmonary bypass in adults

Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery P. Yiu, FRCSa, J. Robin, MRCPb, C.W. Pattison,

Tissue concentrations of endothelins and functional effects of endothelin-receptor activation in human arteries and veins Peter Holm, MD, Anders Franco-Cereceda,

Adverse effects of hyperoxemia during cardiopulmonary bypass

Release of the cerebral protein S-100 into blood after reperfusion during cardiac operations in infants: Is there a relation to oxygen radical–induced.

Metabolic and hemodynamic effects of intravenous glutamate infusion early after coronary operations Rolf Svedjeholm, MD, PhDa, Ingemar Vanhanen, MDa,

David C. Stuesse, MDa, George D. Giraud, MD, PhDb, Angelo A

Patient recovery after intermittent disc escape and spontaneous recession of a mechanical heart valve Francis Robicsek, MD, PhD, Joseph W. Cook, MD

Kai Ihnken, MD The Journal of Thoracic and Cardiovascular Surgery

The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations Kojiro Furukawa, MDa, Hitoshi Ohteki, MDa, Kenji Hirahara,

Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand Weike Tao, MDa, Joseph.

Changes in whole blood lactate levels during cardiopulmonary bypass for surgery for congenital cardiac disease: An early indicator of morbidity and mortality

No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits Christian Olsson, MD, Agneta Siegbahn, MD, PhD,

Elspeth M. Brown, MRCP, Anthony P. Salmon, FRCP, Robert K. Lamb, FRCS

Cardiac cannulation, sodium and water balance, and ANF plasma levels

Nitric oxide mediates fluid accumulation during cardiopulmonary bypass

Effect of cardiopulmonary bypass on pulmonary gas exchange: a prospective randomized study Craig M Cox, Raimondo Ascione, MD, Alan M Cohen, Ian M Davies,

The limits of detectable cerebral perfusion by transcranial doppler sonography in neonates undergoing deep hypothermic low-flow cardiopulmonary bypass

Heart transplantation in patients with previous cardiac operations:

Early markers of major adverse events in children after cardiac operations Trevor Duke, FRACPa, Warwick Butt, FRACPa, Mike South, MD, FRACPb, Tom R. Karl,

Regional cerebral tissue blood flow measured by the colored microsphere method during retrograde cerebral perfusion Keiji Oohara, MDa, Akihiko Usui,

Postbypass effects of delayed rewarming on cerebral blood flow velocities in infants after total circulatory arrest Rosendo A. Rodriguez, MD, PhDa (by.

Human factors and cardiac surgery: A multicenter study

Discussion The Journal of Thoracic and Cardiovascular Surgery

Effect of Nitric Oxide Gas on Platelets During Open Heart Operations

Novel cerebral physiologic monitoring to guide low-flow cerebral perfusion during neonatal aortic arch reconstruction Dean B. Andropoulos, MDa, Stephen.

Natriuresis after cardiopulmonary bypass: Relationship to urodilatin, atrial natriuretic factor, antidiuretic hormone, and aldosterone Jens Sehested,

Goya V. Raikar, MD, Kunikazu Hisamochi, MD, Bao-Lan N

First in line for robotic surgery: Would you want to know?

Minimally invasive direct coronary artery bypass, percutaneous transluminal coronary angioplasty, and stent placement for left main stenosis William.

Masao Takahashi, MD, Shinichiro Yamamoto, MD, Shigeki Tabata, MD

Gary E. Hill, MD, FCCMa,b, Anselmo Alonso, MDc, John R

Y.John Gu, MD, PhD, Piet W. Boonstra, MD, PhD, Willem van Oeveren, PhD

Contribution of hyperoxia to lipid peroxidation in coronary artery operations: Should we keep a low oxygen tension? Leonidas Hadjinikolaou, MD, Andrew.

Presentation transcript:

Tirofiban provides “platelet anesthesia” during cardiopulmonary bypass in baboons Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L. Anderson, MDa, Joseph H. Gorman, MDa, Cezary Marcinkiewicz, PhDb, Robert J. Gould, PhDc, Stefan Niewiarowski, MD, PhDb, L.Henry Edmunds, MDa The Journal of Thoracic and Cardiovascular Surgery Volume 113, Issue 1, Pages 182-193 (January 1997) DOI: 10.1016/S0022-5223(97)70414-8 Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 1 Heart rate, cardiac output, and mean arterial blood pressure (ABP) before, during, and after CPB for 4 groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 1 Heart rate, cardiac output, and mean arterial blood pressure (ABP) before, during, and after CPB for 4 groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 2 Hematocrit-corrected platelet counts before, during, and after CPB for four groups. Platelet counts are standardized as a percentage of BASELINE for each time point of the group. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 3 Platelet aggregation to adenosine diphosphate (ADP) before, during, and after CPB for four groups. Data points are standardized as a percentage of BASELINE for each time point of the group. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 4 Hematocrit corrected βTG release before, during, and after CPB for four groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 5 Template bleeding times before, during, and after CPB for four groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are the mean ± standard error of the mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. †Significant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. The Journal of Thoracic and Cardiovascular Surgery 1997 113, 182-193DOI: (10.1016/S0022-5223(97)70414-8) Copyright © 1997 Mosby, Inc. Terms and Conditions